VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Rhea-AI Summary

VYNE Therapeutics announced that two abstracts reporting positive preclinical and Phase 1b data of their novel BET inhibitor, VYN201, have been selected for presentation at the 2024 Society for Investigative Dermatology Annual Meeting. The company aims to develop VYN201 as a differentiated therapy for nonsegmental vitiligo.

Positive

• Selection of two abstracts for presentation at the prestigious 2024 Society for Investigative Dermatology Annual Meeting is a significant achievement for VYNE Therapeutics, showcasing the importance of their research in the field of immuno-inflammatory conditions.

• The positive preclinical and Phase 1b data for VYN201 highlight the potential of the novel BET inhibitor as an innovative therapy for nonsegmental vitiligo, positioning VYNE for future success in the treatment of this condition.

• The acknowledgment of the research by researchers and clinicians at the upcoming SID Annual Meeting indicates the growing interest and support for VYNE's efforts in developing proprietary and differentiated therapies for immuno-inflammatory conditions.

Negative

• None.

• Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo
  

BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced two abstracts reporting results for its novel BET inhibitor, VYN201, have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA.

“We look forward to sharing our preclinical and Phase 1b data for VYN201 with researchers and clinicians at the upcoming SID Annual Meeting,” said Iain Stuart, Ph.D., Chief Scientific Officer of VYNE. “Our data support the advancement of VYN201 as a differentiated therapy for the potential treatment of nonsegmental vitiligo.”

Presentation Details:

1.	Title:	Preclinical studies: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
	Final ID Number:	LB1055
	Session:	Select E-Poster Discussions (Session 1): Late Breaking Abstracts
	Session Category:	Translational Studies and Early Preclinical to Clinical
	Presenter:	Dr. Iain Stuart
	Session Date/Time:	Thursday, May 16, 2024, 5:00-6:30 p.m. CDT
	Location:	Trinity Exhibit Hall, Stage 5

2.	Title:	Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
	Final ID Number:	LB1056
	Session:	Concurrent Mini-Symposium 18: Late Breaking Abstracts
	Session Category:	Translational Studies and Early Preclinical to Clinical
	Presenter:	Dr. Iain Stuart
	Session Date/Time:	Saturday, May 18, 2024, 10:00 a.m.-12:30 p.m. CDT
	Location:	Cortez C/D

About Vitiligo
Vitiligo is a chronic autoimmune depigmenting disorder of the skin, characterized by the loss of pigment producing cells known as melanocytes. Vitiligo is the most common depigmenting skin condition, with a prevalence estimated at 0.5-2.0% of the world population.¹ There is currently only one FDA-approved product for the treatment of vitiligo. Nonsegmental vitiligo is the most common type of vitiligo.

About VYN201
VYN201 is a pan-bromodomain BET inhibitor designed to be locally administered as a “soft” drug to address diseases involving multiple, diverse inflammatory cell signaling pathways, while providing low systemic exposure. In addition to demonstrating clinical proof-of-concept in vitiligo, VYN201 has produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity in several preclinical models (using several different routes of administration).

About the VYN201 Phase 1b Study in Vitiligo
The Phase 1b trial was a 16-week open-label trial assessing the safety, tolerability, pharmacokinetics, and exploratory efficacy of a once-daily topical formulation of VYN201 in 29 patients with active nonsegmental vitiligo in three dose cohorts (0.5%, 1.0% and 2.0% concentrations). On October 30, 2023, VYNE announced that significant clinical improvement was observed in the 1.0% and 2.0% cohorts, with rapid onset of action and a dose-dependent response. The mean percentage reduction in facial vitiligo area scoring index score from baseline after 16 weeks of treatment was 7.5%, 30.2% and 39.0% for the 0.5%, 1.0% and 2.0% cohorts, respectively. VYN201 was generally well tolerated with no clinically relevant treatment emergent adverse events across all dose cohorts.

About BET Inhibitors
BET proteins play a key role in regulating gene transcription via epigenetic interactions (“reading”), and recent research has determined a key role for these proteins in regulating B cell and T cell activation and subsequent inflammatory processes. As epigenetic readers, BET proteins regulate the recruitment of transcriptional factors that are key to the production of several pro-inflammatory cytokines. BET inhibitors have the potential to treat a range of immuno-inflammatory and fibrotic diseases by blocking pro-inflammatory cytokine transcription with additional potential in myeloproliferative neoplastic disorders.

^{1. Rosmarin et al, Lancet (2020);396:110-120.}

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain inhibitors, which comprise its InhiBET™ platform, include a locally administered pan-BD BET inhibitor (VYN201) and an orally available BD2-selective BET inhibitor (VYN202) that were licensed from Tay Therapeutics Limited. 

For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Cautionary Statement Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the benefits of VYN201 as a potential therapy for nonsegmental vitiligo. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: VYNE’s ability to successfully develop its product candidates; the timing of commencement of future preclinical studies and clinical trials; VYNE’s ability to complete and receive favorable results in, clinical trials for its product candidates; VYNE’s intentions and its ability to obtain additional funding, either through equity or debt financing transactions or collaboration arrangements; and VYNE’s ability to comply with various regulations applicable to its business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Annual Report on Form 10-K for the year ended December 31, 2023, and VYNE’s other filings from time to time with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.

Investor Relations:

John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@vynetx.com

FAQ

What was announced by VYNE Therapeutics regarding VYN201 at the 2024 Society for Investigative Dermatology Annual Meeting?

VYNE Therapeutics announced the selection of two abstracts presenting positive preclinical and Phase 1b data for their novel BET inhibitor, VYN201, for presentation at the event.

What is the focus of the presentations at the SID Annual Meeting regarding VYN201?

The presentations will focus on the translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of nonsegmental vitiligo.

Who will be presenting the data for VYN201 at the SID Annual Meeting?

Dr. Iain Stuart, the Chief Scientific Officer of VYNE Therapeutics, will be presenting the preclinical and Phase 1b data for VYN201 at the event.

When and where will the presentations on VYN201 take place at the SID Annual Meeting?

The presentations for VYN201 will take place on May 16, 2024, from 5:00-6:30 p.m. CDT at the Trinity Exhibit Hall, Stage 5, and on May 18, 2024, from 10:00 a.m.-12:30 p.m. CDT at Cortez C/D.

What is the goal of developing VYN201 as mentioned by VYNE Therapeutics?

VYNE Therapeutics aims to develop VYN201 as a differentiated therapy for the potential treatment of nonsegmental vitiligo, based on the positive data presented at the SID Annual Meeting.